Use of D-Enantiomeric Peptide Ligands of Monomeric Tau for the Therapy of Various Tauopathies

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes a set of specially designed D-enantiomeric peptides that can selectively bind to the monomeric form of the tau protein. These peptides stabilize normal tau and prevent it from aggregating into toxic oligomers or fibrils – a key process in the development of tauopathies such as Alzheimer's disease. Furthermore, the peptides can potentially disassemble existing tau aggregates, making them a promising therapeutic option for the treatment of a range of tau-related neurodegenerative diseases.

Use CasesContent extracted from patent full text and abstract with AI.

• Development of drugs to treat Alzheimer's disease by targeting and stabilizing tau proteins.
• Therapy for other tauopathies such as frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, and subacute sclerosing panencephalitis.
• Research tool in neuroscience to study tau protein conformation, aggregation, and related cell toxicity.
• Potential adjunct therapy in combination with other neurodegenerative disease treatments.
• Development of diagnostic agents that can detect tau conformational states in research or clinical settings.

BenefitsContent extracted from patent full text and abstract with AI.

• First-in-class ability to both prevent formation and promote clearance of toxic tau aggregates, addressing a fundamental cause of tauopathies.
• High specificity and affinity for monomeric tau, reducing risk of off-target effects.
• Composed of D-amino acids, offering exceptional stability against enzymatic degradation in biological fluids and increased in vivo half-life.
• Potential to provide disease-modifying effects that current symptomatic treatments for tauopathies cannot offer.
• Versatile peptide design allows for further functionalization, such as drug conjugation or enhanced blood-brain barrier permeability.
• Could significantly slow or halt disease progression in Alzheimer's and related neurodegenerative conditions, improving patient outcomes.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a peptide, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, or SEQ ID NO. 2, or SEQ ID NO. 3, or SEQ ID NO. 4, or SEQ ID NO. 5, or SEQ ID NO. 6, or SEQ ID NO. 7 and homologues, fragments and parts thereof, and to such a peptide for use in the treatment of tauopathies.